

Novartis India Limited Registered Office: Sandoz House Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018 India

Tel +91 22 2495 8400 Fax +91 22 2495 0221

CIN No. L24200MH1947PLC006104

Website: www.novartis.in

Email: india.investors@novartis.com

The Secretary
The Stock Exchange, Mumbai
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

July 14, 2016

Statement of Investor Complaints/Grievances pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for the Quarter Ended June 30, 2016

Dear Sirs,

Pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, please find enclosed statement of investor complaints/grievances for the quarter ended June 30, 2016.

Thanking you.

Yours sincerely,

For Novartis India Limited

Monaz Noble Chief Financial Officer &

Whole Time Director

Encl.: as above

Girish Tekchandani Company Secretary & Compliance Officer



Novartis India Limited Registered Office: Sandoz House

Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018

India Tel +91 22 2495 8400 Fax +91 22 2495 0221

CIN No. L24200MH1947PLC006104

Website: www.novartis.in

Email: india.investors@novartis.com

Name of the Company: Novartis India Limited

Scrip Code: 500672

Statement of Investor Complaints/Grievances pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for the Quarter Ended June 30, 2016

Particulars	Number of Complaints
Complaints pending as on 01.04.2016	01
Complaints received during 01.04.2016 to 30.06.2016	20
Complaints resolved during 01.04.2016 to 30.06.2016	21
Complaints pending as on 30.06.2016	Nil

For Novartis India Limited

Monaz Noble Chief Financial Officer &

Whole Time Director

Girish Tekchandani Company Secretary & Compliance Officer